BS
BSEM.US BioStem Technologies, Inc. Common Stock
- Market cap
- USD 20.1M
- P/E
- 1.2x
- P/B
- 0.87x
- ROE
- -39.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is BSEM.US undervalued?
Graham numberThe Graham number of BioStem Technologies, Inc. Common Stock cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BioStem Technologies, Inc. Common Stock fundamental analysis
No fundamental analysis for BioStem Technologies, Inc. Common Stock yet.
BioStem Technologies, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BioStem Technologies, Inc. Common Stock
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a human connective tissue matrix compromised of amniotic tissue intended for wound covering; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective …
Full company profileBioStem Technologies, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BioStem Technologies, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 152K | 607K | 329K | 1.02M | 2.63M | 2.52M | 4.34M | 6.88M | 16.7M | 302M | 39.1M |
| Gross Profit | 84.6K | 213K | 179K | 415K | 1.31M | 1.25M | 2.87M | 5.99M | 15.4M | 288M | 32.5M |
| Operating Income | -2.36M | -3.73M | -4.83M | -7.77M | -5.68M | -1.84M | -1.61M | -4.68M | -7.78M | 31.2M | -9.12M |
| EBITDA | - | - | -4.63M | -7.28M | -5.38M | -1.59M | -602K | -6.40M | -7.55M | 31.5M | -7.97M |
| Net Income | -2.38M | -3.96M | -4.84M | -7.59M | -6.34M | -2.39M | -1.45M | -7.07M | -8.48M | 31.9M | -10.9M |
| EPS | - | - | - | - | - | -0.26 | - | -0.58 | -0.52 | 1.92 | -0.61 |
| Balance Sheet | |||||||||||
| Total Assets | 2.94M | 2.74M | 3.03M | 4.30M | 3.15M | 2.67M | 2.67M | 3.47M | 14.6M | 140M | 48.8M |
| Total Liabilities | 1.29M | 2.26M | 1.57M | 5.97M | 7.09M | 8.30M | 8.47M | 7.42M | 15.5M | 99.5M | 21.2M |
| Shareholders' Equity | 1.64M | 481K | 1.46M | -1.67M | -3.94M | -5.63M | -5.79M | -3.95M | -984K | 40.9M | 27.6M |
| Cash & Short-term Investments | 0.00 | 0.00 | 0.00 | 1.18M | 141K | 101K | 340K | 772K | 239K | 22.8M | 6.96M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -354K | -1.69M | -1.65M | -3.66M | -846K | -582K | -109K | -1.64M | -3.50M | 24.5M | - |
| Capital Expenditure | 1.30M | 717K | 148K | 199K | 134K | 0.00 | 42.8K | 244K | 210K | 427K | 3.22M |
| Free Cash Flow | - | - | -2.04M | -3.86M | -979K | -582K | -152K | -2.11M | -3.71M | 24.1M | - |
| Ratios | |||||||||||
| ROE | -144.8% | -822.7% | -330.8% | - | - | - | - | - | - | 78.0% | -39.6% |
| ROA | -81.1% | -144.6% | -159.6% | -176.6% | -200.8% | -89.5% | -54.1% | -204.1% | -58.3% | 22.7% | -22.4% |
| Net Profit Margin | -1,570.9% | -651.8% | -1,473.7% | -746.7% | -240.8% | -94.7% | -33.3% | -102.9% | -50.8% | 10.6% | -28.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
BioStem Technologies, Inc. Common Stock dividends
BioStem Technologies, Inc. Common Stock has not paid dividends in the last 9 fiscal years.
Last stock split: 1:400 on Jan 29, 2015.
Who owns BioStem Technologies, Inc. Common Stock
- Insiders 30.54%
- Institutions 16.09%
- Public & others 53.37%
- Shares outstanding 19.2M
- Free float 14.6M
BioStem Technologies, Inc. Common Stock company profile
- Company name
- BioStem Technologies, Inc. Common Stock
- Ticker
- BSEM.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 73
- Fiscal year end
- December
- Address
- 4901 Northwest 17th Way, Fort Lauderdale, FL, United States, 33309
- Phone
- 954 380 8342
- Website
- biostemtechnologies.com
About BioStem Technologies, Inc. Common Stock
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a human connective tissue matrix compromised of amniotic tissue intended for wound covering; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
BioStem Technologies, Inc. Common Stock management
10- Mr. Jason V. MatuszewskiCEO, President, Secretary & Chairman · born 1986
- Mr. Brandon PoeChief Financial Officer · born 1969
- Mr. Andrew Van Vurst CTBSCOO & Director · born 1991
- Mr. Michael A. Fortunato CPAChief Accounting Officer · born 1967
- Mr. Noah AgronVice President of Corporate Finance & Strategy
- Ms. Katherine GorrellChief Legal & Compliance Officer · born 1977
- Mr. Jeff HumkeVice President of Human Resources
- Dr. David M. WoynarowskiChief Medical Officer
- Mr. Larry JonesChief Revenue Officer
- Dr. Irmgard Huber M.D.International Medical Advisor & Interim Chief Medical Officer